Date: 2016-02-16
Type of information: Grant
Company: Apogenix (Germany)
Investors: German Federal Ministry of Education and Research (BMBF) (Germany)
Amount: €3 Million
Funding type: grant
Planned used: The funds will be used for the further development of lead immuno-oncology candidate APG101 as a personalized therapy for the treatment of glioblastoma. The goal of the CancerMark project is to confirm the efficacy of APG101 in an additional clinical trial and validate a companion diagnostic test to analyze the biomarker associated with the CD95 ligand.
The efficacy of CD95 ligand inhibitor APG101 has been demonstrated in a controlled phase II proof-of-concept trial in patients with recurrent glioblastoma. Glioblastoma patients expressing a certain biomarker associated with the CD95 ligand experienced the greatest benefit from treatment with APG101. The median overall survival rate in biomarker-positive patients treated with APG101 more than doubled to 16 months compared to patients treated with radiotherapy
alone. Apogenix’ main partner for the CancerMark project is R-Biopharm. In July 2015, Apogenix and R-Biopharm entered into a cooperation to develop companion diagnostic tests for APG101.
The CancerMark project was initiated in February 2016, and the funding period is three years.
Others: * On February 16, 2016, Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it has received funding approval in the amount of €3 million from the German Federal Ministry of Education and Research for the so-called CancerMark project.
Therapeutic area: Cancer - Oncology
